SCG
VIVO

Strategic Capital Group’s Meridian Bioscience Inc VIVO Stock Holding History

Strategic Capital Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,037
Closed -$22K – 315
2014
Q1 		$22K Buy
+1,037
New +$23.8K 0.01% 273

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
PIM
Perkins Investment Management Chicago, Illinois $8.09B AUM 25.47% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Strategic Capital Group's VIVO Position: Q2 2014 in Review

Strategic Capital Group sold out of Meridian Bioscience Inc (VIVO) in Q2 2014, closing a stake of 1,037 shares — an estimated $22K sold.

Strategic Capital Group first reported a position in VIVO in Q1 2014 and held it in 1 quarter. The position peaked at $22K in Q1 2014. 161 funds tracked by Wall St. Rank hold VIVO as of Q2 2014.

  • Strategic Capital Group reported no remaining Meridian Bioscience Inc position as of Q2 2014 after selling out during the quarter.
  • Strategic Capital Group sold 1,037 Meridian Bioscience Inc shares in Q2 2014, an estimated $22K.
  • Strategic Capital Group first reported a position in Meridian Bioscience Inc in Q1 2014 and held it in 1 quarter.
  • Strategic Capital Group's Meridian Bioscience Inc position peaked at $22K in Q1 2014.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2014.

Based on Strategic Capital Group's 13F filing for Q2 2014, filed 14 Jul 2014.